Glucagon-like peptide-1 agonism - GLP-1, common in obesity medicines - is not essential to weight management, according to preclinical research led by Richard DiMarchi and Matthias Tschöp, with funding from their startup company Bluewater Biosciences.
Yeah but who has time to read. I’m just gonna jump in and comment. /s
Honestly, I love DiMarchi’s approach.